# Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

> **NCT01109264** · PHASE2 · COMPLETED · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 147 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Bendamustine hydrochloride injection
- **DRUG:** Chlorambucil

## Key facts

- **NCT ID:** NCT01109264
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2013-06
- **Final completion:** 2013-08
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2013-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01109264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01109264, "Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01109264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*